Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu) vipivotide tetraxetan), ...

Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate […] ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

One part of navigating the prostate cancer experience has been PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan), a radioligand therapy (RLT) designed to target metastatic castration-resistant ...

Most recently, Russell has worked to bring Pluvicto to Baton Rouge — a federal Food and Drug Administration-approved, breakthrough medication for patients with advanced prostate cancer that has ...

Don Bryant, Indiana resident, U.S. Army veteran, and prostate cancer survivor who received treatment with Pluvicto™ therapy in clinical trial Philip Low, Purdue Institute for Cancer Research member, ...

FRANKFURT, June 2 (Reuters) - Novartis (NOVN.S), opens new tab said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...